Matinas BioPharma Hlds

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Matinas BioPharma advances MAT2203, faces financial challenges, and extends cash runway

Matinas BioPharma's progress on MAT2203 and positive feedback position the company well in the infectious disease treatment market.
Financially, the company faces challenges with no revenue, high expenses, and a need to carefully manage cash reserves for sustained operations.
Opportunities lie in advancing MAT2203 towards Phase III trials, exploring new therapeutic areas, and extending cash runway for future growth.
Overall, Matinas BioPharma's focus on innovation and strategic partnerships sets the stage for potential growth and market leadership in infectious disease treatments.

Matinas BioPharma reports improved Q2 performance and advances key drug programs

Matinas BioPharma's Q2 2024 performance reflects improved cost management and financial stability, supported by a strengthened cash position and ongoing progress in key drug development programs.
While challenges persist in revenue generation and trial timelines, the company's strategic strengths in product pipeline expansion and innovation present opportunities for future growth and market success.
Overall, Matinas BioPharma's focus on advancing key drug candidates and addressing clinical needs in fungal infections positions the company for potential revenue growth and market leadership in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Ampio Pharmaceuticals Inc

Great Panther Silver

Gulfport Energy Corp

Ferroglobe

Turquoise Hill Resources

Tanzanian Royalty Exploration

If you're itching for a little excitement in your investing, these cheap stocks under $1 might be just what you're looking for. The post 7 Cheap Stocks Under $1 That Deserve A Second Look appeared first on InvestorPlace.

7 Cheap Stocks Under $1 That Deserve A Second Look

BEDMINSTER, N.J., Sept.  14, 2020  (GLOBE NEWSWIRE) --  Matinas BioPharma Holdings, Inc.  (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an independent director and a member of the audit committee, effective Monday, September 14, 2020.

Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors

Topline data expected first quarter 2021 Topline data expected first quarter 2021

Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®

BEDMINSTER, N.J., Aug.  26, 2020  (GLOBE NEWSWIRE) --  Matinas BioPharma Holdings, Inc.  (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview and host one-on-one meetings during two upcoming virtual investor conferences.

Matinas BioPharma to Participate in Two Upcoming Virtual Investor Conferences

Data published in Antimicrobial Agents and Chemotherapy demonstrate MAT2203 (oral amphotericin B) is well tolerated without the side effects commonly seen with IV amphotericin B Data published in Antimicrobial Agents and Chemotherapy demonstrate MAT2203 (oral amphotericin B) is well tolerated without the side effects commonly seen with IV amphotericin B

Matinas BioPharma Announces Publication of Results from Phase 1 Portion of the EnACT Study Investigating Safety and Tolerability of MAT2203

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2020 Results - Earnings Call Transcript

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Lags Revenue Estimates

On Monday, August 10, Matinas BioPharma Hldgs (AMEX: MTNB) will release its latest earnings report.

Earnings Preview for Matinas BioPharma Hldgs

BEDMINSTER, N.J., Aug.  04, 2020  (GLOBE NEWSWIRE) --  Matinas BioPharma Holdings, Inc.  (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to participate in a fireside chat during the BTIG Virtual Biotech Conference 2020 on Tuesday, August 11, 2020 at 9:00 a.m. ET.

Matinas BioPharma to Participate in the BTIG Virtual Biotech Conference 2020

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BEDMINSTER, N.J., July  28, 2020  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. ET to discuss operational and financial results for the second quarter ended June 30, 2020.

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2020 Financial and Operational Results on August 10, 2020

Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Matinas BioPharma (MTNB) in Focus: Stock Moves 6% Higher

-   Topline data from ENHANCE-IT study of MAT9001 vs. Vascepa® expected in Q1 2021   - 

Matinas BioPharma Resumes Enrollment in the ENHANCE-IT and EnACT Clinical Trials

As of late, it has definitely been a great time to be an investor of Matinas BioPharma

Will Matinas BioPharma Continue to Surge Higher?

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1 2020 Results - Earnings Call Transcript

Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates

BEDMINSTER, N.J., March  31, 2020  (GLOBE NEWSWIRE) --  Matinas BioPharma Holdings, Inc.  (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States District Court decision to invalidate patents related to Amarin Corporation’s Vascepa and also provided an update on the effect of the rapidly evolving COVID-19 pandemic on its business operations and clinical development programs. 

Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q4 2019 Results - Earnings Call Transcript

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q4 Loss, Misses Revenue Estimates

Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020

Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®

President of American Board of Clinical Lipidology and nationally recognized expert in cardiovascular disease prevention and the diagnosis and treatment of cholesterol and hypertensive disorders  President of American Board of Clinical Lipidology and nationally recognized expert in cardiovascular disease prevention and the diagnosis and treatment of cholesterol and hypertensive disorders

Matinas BioPharma Appoints James A. Underberg, M.D.

– Part 2 efficacy portion of EnACT expected to commence Q1 2020 –

Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

DURECT

Northern Oil and Gas

Carrols Restaurant Group

VBI Vaccines

While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.

5 Stocks Under $5 With Colossal Growth Prospects

Amneal Pharmaceuticals

Collegium Pharmaceutical

KalVista Pharma

Prospects Appear Bright for Small Drug Industry in 2020

News for Matinas BioPharma Hlds Stock (MTNB)